Biotinylated Human LRRC15 / LIB Protein, His,Avitag™ (MALS verified)
分子别名（Synonym）
Leucine-rich repeat-containing protein 15, LRRC15, LIB, hLib
表达区间及表达系统（Source）
Biotinylated Human LRRC15, His,Avitag (LR5-H82E4) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 538 (Accession # Q8TF66-1).
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 61.5 kDa. The protein migrates as 70-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
LRRC15（富含亮氨酸重复序列蛋白15）亦被称为LIB或hLib。该蛋白在多种实体瘤中呈高表达，广泛存在于众多实体瘤（如乳腺、头颈部、肺、胰腺肿瘤）的基质成纤维细胞上，并直接表达于部分间充质来源的癌细胞（如肉瘤、黑色素瘤、胶质母细胞瘤）。TGFβ可在活化成纤维细胞（αSMA+）及间充质干细胞上诱导LRRC15表达。这些研究共同表明，LRRC15可作为新型癌症相关成纤维细胞及间充质标记物，为治疗伴有LRRC15阳性基质促纤维增生的肿瘤或间充质来源肿瘤提供了潜在治疗靶点。ABBV-085是一种靶向LRRC15的抗体偶联药物，其携带单甲基澳瑞他汀E（MMAE）载荷，临床前研究显示该药物单用或与标准疗法联用时，在LRRC15基质阳性/癌细胞阴性模型及LRRC15癌细胞阳性模型中均展现出显著疗效。
关键字： LRRC15;LRRC15蛋白;LRRC15重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。